Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor

Clinical Cancer Research

Volumn 9, Issue 2, 2003, Pages 586-593

  Lockhart, A Craig ^a   Braun, Rod D ^a   Yu, Daohai ^a   Ross, Joel R ^a   Dewhirst, Mark W ^a   Humphrey, Jeffrey S ^b   Thompson, Seth ^b   Williams, Kathleen M ^b   Klitzman, Bruce ^a   Yuan, Fan ^a   Grichnik, James M ^a   Proia, Alan D ^a   Conway, Delina A ^a   Hurwitz, Herbert I ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BACITRACIN; CYTOTOXIC AGENT; MATRIX METALLOPROTEINASE INHIBITOR; REBIMASTAT;

ADULT; AGED; ANGIOGENESIS; ARTICLE; ASSAY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; REPRODUCIBILITY; SKIN BIOPSY; TUMOR VASCULARIZATION; VASCULARIZATION; WOUND;

ANTINEOPLASTIC AGENTS; BIOPSY; HUMANS; IMIDAZOLES; MATRIX METALLOPROTEINASES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; ORGANIC CHEMICALS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0037314611     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Folkman, J. What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst., 82: 4-6, 1990.
2. Weidner, N., Carroll, P. R., Flax, J., Blumenfeld, W., and Folkman, J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am. J. Path., 143: 401, 1993.
3. Gasparini, G., Weidner, N., Bevilacqua, P., Maluta, S., Dalla Palma, P., Caffo, O., Barbaresch, i. M., Boracch, i. P., Marubin, i. E., and Pozza, F. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic vessel invasion are relevant prognostic markers in node-negative breast carcinoma. J. Clin. Oncol., 12: 454-466, 1994.
4. Hayes, D. F. Angiogenesis and breast cancer. Hematol. Oncol. Clin. N. Am., 8: 51-71, 1994.
5. Ausprunk, D. H., Knighton, D. R., and Folkman, J. Vascularization of normal and neoplastic tissues grafted to the chick chorioallantois. Role of host and preexisting graft blood vessels. Am. J. Pathol., 79: 597-628, 1975.
6. Clark, R. A., DellaPelle, P., Manseau, E., Lanigan, J. M., Dvorak, H. F., and Colvin, R. B. Blood vessel fibronectin increases in conjunction with endothelial cell proliferation and capillary ingrowth during wound healing. J. Investig. Dermatol., 79: 269-276, 1982.
7. Peters, K. G., De Vries, C., and Williams, L. T. Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth. Proc. Natl. Acad. Sci. USA, 90: 8915-8919, 1993.
8. Folkman, J. Seminars in Medicine of the Beth Israel Hospital. Boston. Clinical applications of research on angiogenesis. N. Eng. J. Med., 333: 1757-1763, 1995.
9. Harris, A. Antiangiogenesis for cancer therapy. Lancet, 349: S13-15, 1997.
10. Rak, J., and Kerbel, R. S. Treating cancer by inhibiting angiogenesis: new hopes and potential pitfalls. Cancer Metastasis Rev., 15: 231-236, 1996.
11. Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y. N., and Brem, H. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int. J. Cancer, 57: 920-925, 1994.
12. Klagsbrun, M., and D'Amore, P. A. Regulators of angiogenesis. Annu. Rev. Physiol., 53: 217-239, 1991.
13. Pluda, J. M. Tumor-associated angiogenesis: mechanisms, clinical implications, and therapeutic strategies. Semin. Oncol., 24: 203-218, 1997.
14. Folkman, J. Angiogenesis and angiogenesis inhibition: an overview. EXS, 79: 1-8, 1997.
15. Folkman, J., and Shing, Y. Angiogenesis. J. Biol. Chem., 267: 10931-10934, 1992.
16. Lewis, C. E., Leek, R., Harris, A., and McGee, J. O. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J. Leukoc. Biol., 57: 747-751, 1995.
17. Stetler-Stevenson, W. G., Aznavoorian, S., and Liotta, L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu. Rev. Cell Biol., 9: 541-573, 1993.
18. Yamamoto, M., Sawaya, R., Mohanam, S., Rao, V. H., Bruner, J. M., Nicolson, G. L., Ohshima, K., and Rao, J. S. Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression. J. Neuro-Oncol., 22: 139-151, 1994.
19. Mignatti, P., Morimoto, T., and Rifkin, D. B. Basic fibroblast growth factor released by single, isolated cells stimulates their migration in an autocrine manner. Proc. Natl. Acad. Sci. USA, 88: 11007-11011, 1991.
20. Ito, K., Ryuto, M., Ushiro, S., Ono, M., Sugenoya, A., Kuraoka, A., Shibata, Y., and Kuwano, M. Expression of tissue-type plasminogen activator and its inhibitor couples with development of capillary network by human microvascular endothelial cells on Matrigel. J. Cell. Physiol., 162: 213-224, 1995.
21. Mandriota, S. J., Seghezzi, G., Vassalli, J. D., Ferrara, N., Wasi, S., Mazzieri, R., Mignatti, P., and Pepper, M. S. Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J. Biol. Chem., 270: 9709-9716, 1995.
22. Mignatti, P., Mazzieri, R., and Rifkin, D. B. Expression of the urokinase receptor in vascular endothelial cells is stimulated by basic fibroblast growth factor. J. Cell Biol., 113: 1193-1201, 1991.
23. Tsai, J. C., Goldman, C. K., and Gillespie, G. Y. Vascular endothelial growth factor in human glioma cell lines: induced secretion by EGF, PDGF-BB, and bFGF. J. Neurosurg., 82: 864-873, 1995.
24. Frank, S., Hubner, G., Breier, G., and Longaker, M. T. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. J. Biol. Chem., 270: 12607-12613, 1995.
25. Dvorak, H. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Eng. J. Med., 315: 1650-1659, 1986.
26. Brown, P., Bloxidge, R., Stuart, N., Garter, K., and Carmichael, J. Association between expression of activated 72-kilodalton gelatinase and tumor spread in non-small-cell lung carcinoma. J. Natl. Cancer Inst., 85: 574-578, 1993.
27. Davies, B., Waxman, J., Wasan, H., Abel, P., Williams, G., Krausz, T., Neal, D., Thomas, D., Hanby, A., and Balkwill, F. Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res., 53: 5365-5369, 1993.
28. Murray, G., Duncan, M., O'Neil, P., Melvin, W., and Fothergill, J. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med., 2: 461-462, 1996.
29. Nomura, H., Fujimoto, N., Seiki, M., Mai, M., and Okada, Y. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. Int. J. Cancer, 69: 9-16, 1996.
30. Walther, M., Kleiner, D., Lubensky, I., Pozzatti, R., Nyguen, T., Gnarra, J., Hurley, K., Venzon, D., Linehan, W., and Stetler-Stevenson, W. Progelatinase A mRNA expression in cell lines derived from tumors in patients with metastatic renal cell carcinoma correlates inversely with survival. Urology, 50: 295-301, 1997.
31. Zeng, Z., Huang, Y., Cohen, A., and Guillem, J. Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase-9. J. Clin. Oncol., 14: 3133-3140, 1996.
32. Vu, T., Shipley, J., Bergers, G., Berger, J., Helms, J., Hanahan, D., Shapiro, S., Senior, R., and Werb, Z. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell, 93: 411-422, 1998.
33. Itoh, T., Tanioka, M., Yoshida, H., Yoshioka, T., Nishimoto, H., and Itohara, S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res., 58: 1048-1051, 1998.
34. Heath, E. I., and Grochow, L. B. Clinical potential of matrix metalloprotease inhibitors in cancer therapy. Drugs, 59: 1043-1055, 2000.
35. Curran, S., and Murray, G. I. Matrix metalloproteinases in tumour invasion and metastasis. J. Pathol., 189: 300-308, 1999.
36. Bramhall, S. R., Schulz, J., Nemunaitis, J., Brown, P. D., Baillet, M., and Buckels, J. A. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br. J. Cancer, 87: 161-167, 2002.
37. Erlichman, C., Adjei, A. A., Alberts, S. R., Sloan, J. A., Goldberg, R. M., Pitot, H. C., Rubin, J., Atherton, P. J., Klee, G. G., and Humphrey, R. Phase I study of the matrix metalloproteinase inhibitor, BAY 12-9566. Ann. Oncol., 12: 389-395, 2001.
38. Rudek, M. A., Figg, W. D., Dyer, V., Dahut, W., Turner, M. L., Steinberg, S. M., Liewehr, D. J., Kohler, D. R., Pluda, J. M., and Reed, E. Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer. J. Clin. Oncol., 19: 584-592, 2001.
39. Sparano, J., Bernardo, P., Gradishar, W., Ingle, J., Zucker, S., and NE, D. Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: an Eastern Cooperative Oncology Group trial (E2196). Am. Soc. Clin. Oncol., 21: 44a, 2002.
40. Naglich, J. G., Jure-Kunkel, M., Gupta, E., Fargnoli, J., Henderson, A. J., Lewin, A. C., Talbott, R., Baxter, A., Bird, J., Savopoulos, R., Wills, R., Kramer, R. A., and Trail, P. A. Inhibition of angiogenesis and metastasis in two murine models by the matrix metalloproteinase inhibitor, BMS-275291. Cancer Res., 61: 8480-8485, 2001.
41. Coussens, L., and Werb, Z. Matrix metalloproteinases and the development of cancer. Chem. Biol (Lond.), 3: 895-904, 1996.
42. Wojtowicz-Praga, S., Torri, J., Johnson, M., Steen, V., Marshall, J., Ness, E., Dickson, R., Sale, M., Rasmussen, H., Chiodo, T., and Hawkins, M. Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol., 16: 2150-2156, 1998.
43. Moses, M. A., Klagsbrun, M., and Shing, Y. The role of growth factors in vascular cell development and differentiation. Int. Rev. Cytol., 161: 1-48, 1995.
44. Wang, D., Donner, D. B., and Warren, R. S. Homeostatic modulation of cell surface KDR and Flt1 expression and expression of the vascular endothelial cell growth factor (VEGF) receptor mRNAs by VEGF. J. Biol. Chem., 275: 15905-15911, 2000.
45. Ezekowitz, R. A., Mulliken, J. B., and Folkman, J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N. Eng. J. Med., 326: 1456-1463, 1992.
46. Slaton, J., Perrotte, P., Inoue, K., Dinney, C., and Fidler, I. Interferon-α-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin. Cancer Res., 5: 2726-2734, 1999.
47. Hurwitz, H. I., Lockhart, A. C., Dewhirst, M. W., Klitzman, B., Yuan, F., Grichnik, J. M., Proia, A. D., Conway, D. A., Beaty, J. K., and Braun, R. D. Evaluation of wound angiogenesis in healthy volunteers: a potential surrogate marker for antiangiogenesis agents. Proc. Am. Assoc. Cancer Res., 41: 168, 2000.
48. Howdieshell, T. R., Callaway, D., Webb, W. L., Gaines, M. D., Procter, C. D., Jr., Sathyanarayana, Pollock, J. S., Brock, T. L., and McNeil, P. L. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation. Journal of Surgical Research, 96: 173-182, 2001.
49. Berbari, P., Thibodeau, A., Germain, L., Saint-Cyr, M., Gaudreau, P., Elkhouri, S., Dupont, E., Garrel, D. R., Elkouri, S., and El-Khouri, S. Antiangiogenic effects of the oral administration of liquid cartilage extract in humans. J. Surg. Res., 87: 108-113, 1999.
50. Streit, M., Velasco, P., Riccardi, L., Spencer, L., Brown, L. F., Janes, L., Lange-Asschenfeldt, B., Yano, K., Hawighorst, T., Iruela-Arispe, L., and Delmar, M. Thrombospondin-1 suppresses wound healing and granulation tissue formation in the skin of transgenic mice. EMBO J., 19: 3272-3282, 2000.
51. O'Brien, P. C., and Fleming, T. R. A paired Prentice-Wilcoxon test for censored paired data. Biometrics, 43: 169-180, 1987.
52. Stetler-Stevenson, W., Hewitt, R., and Corcoran, M. Matrix metal-loproteinases and tumor invasion: from correlation and causality to the clinic. Semin. Cancer Biol., 7: 147-154, 1996.
53. Polverini, P. How the extracellular matrix and macrophages contribute to angiogenesis-dependent diseases. Eur. J. Cancer, 32A: 2430-2437, 1996.
54. Arbiser, J. Angiogenesis and the skin: a primer. J. Am. Acad. Dermatol., 34: 486-497, 1996.
55. St. Croix, B., Rago, C., Velculescu, V., Traverso, G., Romans, K. E., Montgomery, E., Lal, A., Riggins, G. J., Lengauer, C., Vogelstein, B., and Kinzler, K. W. Genes expressed in human tumor endothelium. Science (Wash. DC), 289: 1197-1202, 2000.
56. Banks, R., Forbes, M., Kinsey, S., Stanley, A., Ingham, E., Walters, C., and Selby, P. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer, 77: 956-964, 1998.
57. Kondo, S., Asano, M., Matsuo, K., Ohmori, I., and Suzuki, H. Vascular endothelial growth factor/vascular permeability factor is detectable in the sera of tumor-bearing mice and cancer patients. Biochim. Biophys. Acta, 1221: 211-214, 1994.
58. Vermeulen, P., Salven, P., Benoy, I., Gasparini, G., and Dirix, L. Blood platelets and serum VEGF in cancer patients. Br. J. Cancer, 79: 370-373, 1999.
59. Yeo, K. T., Wang, H. H., Nagy, J. A., Sioussat, T. M., Ledbetter, S. R., Hoogewerf, A. J., Zhou, Y., Masse, E. M., Senger, D. R., and Dvorak, H. F. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res., 53: 2912-2918, 1993.
60. Baird, A., Esch, F., Mormede, P., Ueno, N., Ling, N., Bohlen, P., Ying, S. Y., Wehrenberg, W. B., and Guillemin, R. Molecular characterization of fibroblast growth factor: distribution and biological activities in various tissues. Recent Prog. Horm. Res., 42: 143-205, 1986.
61. Nguyen, M., Watanabe, H., Budson, A. E., Richie, J. P., Hayes, D. F., and Folkman, J. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J. Natl. Cancer Inst., 86: 356-361, 1994.